Trevi Therapeutics Long Term Debt

As of the most recent data (June 2026), TRVI shows a long-term debt of $280K. That compares with $1.2M in the prior-year period — down 77.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, TRVI's long-term debt is now $280K (was $1.2M) — a 77.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Trevi Therapeutics is outperforming or lagging.

Tracking TRVI's long-term debt over time shows whether Trevi Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $280K That compares with $1.2M in the prior-year period — down 77.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Trevi Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $280K) with ownership activity and broader fundamentals.

Trevi Therapeutics's long-term debt is $280K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.